$VALN News

MHRA revokes approval for Valneva’s Ixchiq due to safety frailties

Full Transcript: Valneva Q2 2026 Earnings Call

UK Revokes Approval for Valneva's Chikungunya Shot

Valneva Shares Fall as UK Withdraws Approval for Ixchiq Chikungunya Vaccine

VALN Stock Plunges 7% After-Hours As UK Revokes Valneva’s IXCHIQ Authorization In Latest Market Setback

Valneva ADRs fall as UK revokes IXCHIQ marketing authorization

Valneva Provides Update on IXCHIQ® in the United Kingdom

Declaration of shares and voting rights - Status as of September 30, 2026

Declaration of shares and voting rights - Status as of August 31, 2026

Valneva (VALN) Q2 2026 Earnings Call Transcript

Valneva: The Lyme Royalty Transition Changes The Earnings Model

Why Did VALN Stock Surge 24% Today?

Valneva SE (INRLF) (H1 2026) Earnings Call Highlights: Strategic Pivot and Lyme Vaccine ...

Valneva SE (VALN) Q2 2026 Earnings Call Transcript

Conference Call: Valneva Affirms FY2026 Sales Guidance of $169.795M-$187.360M vs $171.630M Est

Valneva Reports H1 2026 Product Sales Of €64.0M Down From €91.0M YoY, Net Loss Widens To €63.3M From €20.8M YoY

Declaration of shares and voting rights - Status as of July 31, 2026

Valneva to Report First Half 2026 Consolidated Financial Results on August 13, 2026

Declaration voting rights - June 30,2026

Valneva Announces Successful Outcome of its Annual General Meeting